Post - BrainCool | World-class medical cooling systems
BrainCool AB completes recruitment in trial f | EurekAlert!
BrainCool on the benefits of uplisting to Nasdaq First North - BioStock
BrainCool's CEO on the listing announcement from Nasdaq - BioStock
MFN.se > BrainCool > BrainCool AB (publ): BrainCool offentliggör bolagsbeskrivning inför notering på Nasdaq First North Growth Market
Kommuniké från extra bolagsstämma i BrainCool AB (publ) med beslut om utdelning av aktier i PolarCool AB
Braincool på väg från Spotlight till First North
BrainCool AB (publ) investerar tre mkr i PolarCool genom kvittning av fordran
BrainCool aktie (BRAIN) | Alla nyheter, analys, riktkurs… - Börskollen
FDA Breakthrough Device Designation Awarded To BrainCool AB's Cooral System | Medical Product Outsourcing
Braincool AB | Aktiespararna
Veckans Aktie - BrainCool » Finanstid
BrainCool AB (publ) | LinkedIn
BrainCool Seeks De Novo For Device That Prevents Oral Mucositis In Cancer Patients :: Medtech Insight
BrainCool AB (publ) | LinkedIn
Emission: BrainCool - Analyst Group
BrainCool AB: Correction “New order on the US market for IQool™ System” published 2020-02-06
Post - BrainCool | World-class medical cooling systems
BrainCool's IQool™ system aligns with New Ame | EurekAlert!
Organization - BrainCool | World-class medical cooling systems
BrainCool AB (publ) - Exercise period for BrainCool's warrants, BRAIN TO 3, 2019-2022, August 24 – September 7, 2020
BrainCool AB (publ) has established direct sales operations in USA
